Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: May 17, 2023
Breast
cancer
is
a
highly
heterogeneous
disease,
at
both
inter-
and
intra-tumor
levels,
this
heterogeneity
crucial
determinant
of
malignant
progression
response
to
treatments.
In
addition
genetic
diversity
plasticity
cells,
the
tumor
microenvironment
contributes
shaping
physical
biological
surroundings
tumor.
The
activity
certain
types
immune,
endothelial
or
mesenchymal
cells
in
can
change
effectiveness
therapies
via
plethora
different
mechanisms.
Therefore,
deciphering
interactions
between
distinct
cell
types,
their
spatial
organization
specific
contribution
growth
drug
sensitivity
still
major
challenge.
Dissecting
currently
an
urgent
need
better
define
breast
biology
develop
therapeutic
strategies
targeting
as
helpful
tools
for
combined
personalized
treatment.
review,
we
analyze
mechanisms
by
which
affects
characteristics
that
ultimately
result
resistance,
outline
state
art
preclinical
models
emerging
technologies
will
be
instrumental
unraveling
impact
on
resistance
therapies.
Journal of Hematology & Oncology,
Journal Year:
2021,
Volume and Issue:
14(1)
Published: May 31, 2021
Abstract
Cancer
is
a
disease
with
complex
pathological
process.
Current
chemotherapy
faces
problems
such
as
lack
of
specificity,
cytotoxicity,
induction
multi-drug
resistance
and
stem-like
cells
growth.
Nanomaterials
are
materials
in
the
nanorange
1–100
nm
which
possess
unique
optical,
magnetic,
electrical
properties.
used
cancer
therapy
can
be
classified
into
several
main
categories.
Targeting
cells,
tumor
microenvironment,
immune
system,
these
nanomaterials
have
been
modified
for
wide
range
therapies
to
overcome
toxicity
enhance
drug
capacity
well
bioavailability.
Although
number
studies
has
increasing,
approved
nano-drugs
not
increased
much
over
years.
To
better
improve
clinical
translation,
further
research
needed
targeted
delivery
by
nano-carriers
reduce
toxicity,
permeability
retention
effects,
minimize
shielding
effect
protein
corona.
This
review
summarizes
novel
fabricated
use,
discusses
current
limitations
obstacles
that
hinder
translation
from
provides
suggestions
more
efficient
adoption
therapy.
Nature Cancer,
Journal Year:
2022,
Volume and Issue:
3(2), P. 232 - 250
Published: Feb. 24, 2022
Models
that
recapitulate
the
complexity
of
human
tumors
are
urgently
needed
to
develop
more
effective
cancer
therapies.
We
report
a
bank
patient-derived
xenografts
(PDXs)
and
matched
organoid
cultures
from
represent
greatest
unmet
need:
endocrine-resistant,
treatment-refractory
metastatic
breast
cancers.
leverage
PDXs
PDX-derived
organoids
(PDxO)
for
drug
screening
is
feasible
cost-effective
with
in
vivo
validation.
Moreover,
we
demonstrate
feasibility
using
these
models
precision
oncology
real
time
clinical
care
case
triple-negative
(TNBC)
early
recurrence.
Our
results
uncovered
Food
Drug
Administration
(FDA)-approved
high
efficacy
against
models.
Treatment
this
therapy
resulted
complete
response
individual
progression-free
survival
(PFS)
period
than
three
times
longer
their
previous
This
work
provides
valuable
methods
resources
functional
medicine
development
cancer.
Cell Reports,
Journal Year:
2020,
Volume and Issue:
31(11), P. 107762 - 107762
Published: June 1, 2020
There
remains
an
unmet
need
for
preclinical
models
to
enable
personalized
therapy
ovarian
cancer
(OC)
patients.
Here
we
evaluate
the
capacity
of
patient-derived
organoids
(PDOs)
predict
clinical
drug
response
and
functional
consequences
tumor
heterogeneity.
We
included
36
whole-genome-characterized
PDOs
from
23
OC
patients
with
known
histories.
maintain
genomic
features
original
lesion
recapitulate
patient
neoadjuvant
carboplatin/paclitaxel
combination
treatment.
display
inter-
intrapatient
heterogeneity
chemotherapy
targeted
drugs,
which
can
be
partially
explained
by
genetic
aberrations.
PDO
screening
identifies
high
responsiveness
at
least
one
88%
are
valuable
that
provide
insights
into
individual
OC,
complementary
testing.
Generating
multiple
locations
improve
decision
making
increase
our
knowledge
Cells,
Journal Year:
2019,
Volume and Issue:
8(8), P. 889 - 889
Published: Aug. 13, 2019
Patient-derived
xenograft
(PDX)
models
are
created
by
engraftment
of
patient
tumor
tissues
into
immunocompetent
mice.
Since
a
PDX
model
retains
the
characteristics
primary
including
gene
expression
profiles
and
drug
responses,
it
has
become
most
reliable
in
vivo
human
cancer
model.
The
rate
increases
with
introduction
Non-obese
diabetic
Severe
combined
immunodeficiency
(NOD/SCID)-based
immunocompromised
mice,
especially
NK-deficient
NOD
strains
NOD/SCID/interleukin-2
receptor
gamma
chain(IL2Rγ)null
(NOG/NSG)
NOD/SCID/Jak3(Janus
kinase
3)null
(NOJ).
Success
rates
differ
origin:
gastrointestinal
tumors
acquire
higher
rate,
while
is
lower
for
breast
cancers.
Subcutaneous
transplantation
popular
method
to
establish
PDX,
but
some
require
specific
environments,
e.g.,
orthotropic
or
renal
capsule
transplantation.
Human
hormone
treatment
necessary
hormone-dependent
cancers
such
as
prostate
mice
hematopoietic
immune
systems
(humanized
PDX)
powerful
tools
analysis
tumor–immune
system
interaction
evaluation
immunotherapy
response.
A
biobank
equipped
patients’
clinical
data,
gene-expression
patterns,
mutational
statuses,
tissue
architects,
responsiveness
will
be
an
authoritative
resource
developing
biomarkers
chemotherapeutic
predictions,
creating
individualized
therapy,
establishing
precise
medicine.
Journal of Hematology & Oncology,
Journal Year:
2020,
Volume and Issue:
13(1)
Published: July 16, 2020
Abstract
Cancer
is
a
complex
disease
in
which
both
genetic
defects
and
microenvironmental
components
contribute
to
the
development,
progression,
metastasization
of
disease,
representing
major
hurdles
identification
more
effective
safer
treatment
regimens
for
patients.
Three-dimensional
(3D)
models
are
changing
paradigm
preclinical
cancer
research
as
they
closely
resemble
tissue
environment
architecture
found
clinical
tumors
than
bidimensional
(2D)
cell
cultures.
Among
3D
models,
spheroids
organoids
represent
most
versatile
promising
that
capable
recapitulating
heterogeneity
pathophysiology
human
cancers
filling
gap
between
conventional
2D
vitro
testing
animal
models.
Such
systems
powerful
tool
studying
biology,
enabling
us
model
dynamic
evolution
neoplastic
from
early
stages
metastatic
dissemination
interactions
with
microenvironment.
Spheroids
have
recently
been
used
field
drug
discovery
personalized
medicine.
The
combined
use
could
potentially
improve
robustness
reliability
data,
reducing
need
favoring
their
transition
practice.
In
this
review,
we
summarize
recent
advances
these
modeling,
focusing
on
innovative
translational
applications,
looking
at
future
challenges,
comparing
them
widely
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: April 12, 2023
Abstract
Patient-derived
xenograft
(PDX)
models,
in
which
tumor
tissues
from
patients
are
implanted
into
immunocompromised
or
humanized
mice,
have
shown
superiority
recapitulating
the
characteristics
of
cancer,
such
as
spatial
structure
cancer
and
intratumor
heterogeneity
cancer.
Moreover,
PDX
models
retain
genomic
features
across
different
stages,
subtypes,
diversified
treatment
backgrounds.
Optimized
engraftment
procedures
modern
technologies
multi-omics
deep
learning
enabled
a
more
comprehensive
depiction
molecular
landscape
boosted
utilization
models.
These
irreplaceable
advantages
make
an
ideal
choice
studies,
preclinical
trials
novel
drugs,
validating
drug
combinations,
screening
drug-sensitive
patients,
exploring
resistance
mechanisms.
In
this
review,
we
gave
overview
history
process
model
establishment.
Subsequently,
review
presents
strengths
weaknesses
highlights
integration
research.
Finally,
delineated
broad
application
chemotherapy,
targeted
therapy,
immunotherapy,
other
therapies.
ACS Omega,
Journal Year:
2023,
Volume and Issue:
8(16), P. 14290 - 14320
Published: April 10, 2023
Cancer
is
ranked
as
the
second
leading
cause
of
death
globally.
Traditional
cancer
therapies
including
chemotherapy
are
flawed,
with
off-target
and
on-target
toxicities
on
normal
cells,
requiring
newer
strategies
to
improve
cell
selective
targeting.
The
application
nanomaterial
has
been
extensively
studied
explored
chemical
biology
tools
in
theranostics.
It
shows
greater
applications
toward
stability,
biocompatibility,
increased
permeability,
resulting
precise
targeting,
mitigating
shortcomings
traditional
therapies.
nanoplatform
offers
an
exciting
opportunity
gain
targeting
multifunctionality.
advent
nanotechnology,
particular
development
smart
nanomaterials,
transformed
diagnosis
treatment.
large
surface
area
nanoparticles
enough
encapsulate
many
molecules
ability
functionalize
various
biosubstrates
such
DNA,
RNA,
aptamers,
antibodies,
which
helps
theranostic
action.
Comparatively,
biologically
derived
nanomaterials
perceive
advantages
over
produced
by
conventional
methods
terms
economy,
ease
production,
reduced
toxicity.
present
review
summarizes
techniques
theranostics
emphasizes
(such
organic
(NPs),
inorganic
NPs,
carbon-based
NPs).
We
also
critically
discussed
challenges
impeding
their
translation
treatment
diagnostic
applications.
This
concludes
that
use
could
significantly
will
facilitate
new
dimensions
for
tumor
detection
therapy.